Envirotainer has reported a 24% increase in the volume of medicines shipped around the world in its temperature-controlled units.

Envirotainer shipments jumped by a quarter in 2022

23.03.23 03:28

Sofia Wiwen-Nilsson
Head of Marketing and Communications

In 2021, the Envirotainer fleet moved 600m doses. The following year this grew to 744m doses (272 000 pallets).

The reported increase in business follows the cold chain solutions specialist’s expansion of its production site in Rosersberg, just north of Stockholm, in November 2022. The investment will allow Envirotainer to grow its current fleet of 7,500 Federal Aviation Administration (FAA) and European Union Aviation Safety Agency (EASA) certified containers by another 1,300 in 2023.

The Envirotainer fleet covers more than 2,000 pharmaceutical trade lanes in over 100 countries and 300 airports.

With its Releye range, which Envirotainer said includes the biggest thermally-controlled container available, the company aims to ensure minimal or zero temperature deviations on the shipments and virtually zero product loss. Releye also offers integrated live monitoring, which enables a unique insight into product condition, location and progress of the shipment.

The company also supports cryogenic -70°C dry ice shipping for products such as clinical trials, vaccines, diagnostics biospecimen with its CryoSure product line.

Fredrik Linnér, chief business development officer at Envirotainer, said: “The increase in our shipments reflects the huge need for efficient, secure and sustainable cold-chain solutions for transporting sensitive pharmaceuticals.

We will continue to increase capacity, developing our product range and accelerating the digitalization of the cold-chain industry. The need to safely transport pharmaceuticals while minimizing wasted space in precious air cargo is unlikely to disappear. We will be ready to help our customers move life-saving medicines where they need to be.”